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Capecitabine is a highly active oral fluoropyrimidine that is an attractive alternative to 5-fluorouracil in colorectal cancer treatment.
The current study, undertaken in 27 patients with gastrointestinal tumours, aimed to assess the toxicity and potential for significant
pharmacokinetic interactions of a combination regimen incorporating capecitabine with 3-weekly irinotecan (XELIRI). Irinotecan (200
and 250mgm
 2) was administered as a 90-min infusion on day 1 in combination with escalating capecitabine doses (700–
1250mgm
 2 twice daily) administered on days 2–15 of a 3-week treatment cycle. Pharmacokinetics were characterised on days 1
and 2 of the first two cycles. A total of 103 treatment cycles were administered. The principal dose-limiting toxicities were diarrhoea
and neutropenia. Capecitabine 1150mgm
 2 twice daily with irinotecan 250mgm
 2 was identified as the maximum-tolerated dose
and capecitabine 1000mgm
 2 with irinotecan 250mgm
 2 was identified as the recommended dose for further study. Analyses
confirmed that there were no significant pharmacokinetic interactions between the two agents. The combination was clinically active,
with complete and partial responses achieved in heavily pretreated patients. This study indicates that XELIRI is a potentially feasible
and clinically active regimen in patients with advanced gastrointestinal cancer.
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5-Fluorouracil (5-FU) has been the backbone of treatment for
colorectal cancer (CRC) for more than 40 years. During this time, a
number of schedules and regimens have been investigated.
Irinotecan, a topoisomerase I inhibitor, is an effective treatment
in patients with advanced/metastatic CRC unresponsive or
resistant to 5-FU-based chemotherapy. Two pivotal, phase III
studies in metastatic CRC, which demonstrated superior survival
for irinotecan compared with best supportive care and infused 5-
FU-based therapy, established irinotecan as a new agent for the
second-line treatment of 5-FU-pretreated CRC (Cunningham et al,
1998; Rougier et al, 1998). In addition, combination of irinotecan
with intravenous 5-FU/leucovorin (LV) was shown to significantly
improve response rate, time to disease progression (TTP) and
overall survival compared with 5-FU/LV alone in patients with
previously untreated metastatic CRC (Douillard et al, 2000; Saltz
et al, 2000). Recently, however, a high incidence of early treatment-
related deaths was noted with the administration of the weekly
irinotecan plus bolus intravenous 5-FU/LV schedule in this setting,
and it has been suggested that continuous infusion 5-FU may be a
safer option than bolus 5-FU for combination with irinotecan
(Rothenberg et al, 2001).
Capecitabine (Xeloda; F Hoffmann-La Roche, Nutley, NJ, USA)
is an oral fluoropyrimidine carbamate, which was rationally
designed to mimic continuous infusion 5-FU. With capecitabine,
5-FU is generated preferentially in tumour tissue through high
intratumoral concentrations of thymidine phosphorylase (TP)
(Miwa et al 1998; Schu ¨ller et al 2000). Human pharmacokinetic
studies, using validated methods for estimation of capecitabine
and its metabolites, have shown that capecitabine is rapidly and
almost completely absorbed through the gastrointestinal wall
(Reigner et al, 2001). Capecitabine is metabolised to 5-FU via a
three-step enzymatic cascade (Miwa et al 1998). In the first step,
capecitabine is hydrolysed by hepatic carboxylesterase to 50-deoxy-
5-fluorocytidine (50-DFCR), which is in turn converted by cytidine
deaminase to 50-deoxy-5-fluorouridine (50-DFUR), the immediate
precursor of 5-FU. The final step in the activation to 5-FU is
mediated by TP, an enzyme that is highly active in tumour tissue
compared with healthy tissue (Miwa et al, 1998).
Capecitabine is replacing 5-FU in CRC treatment. Two large,
phase III trials including more than 1200 patients have demon-
strated that, as first-line therapy for metastatic CRC, capecitabine
achieves significantly superior response rates, with at least
equivalent TTP and overall survival compared with 5-FU/LV (Hoff
et al, 2001; Van Cutsem et al, 2001, 2004). Notably, the superior
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stumour response rate for capecitabine was particularly pro-
nounced among the subpopulation of patients who had received
prior adjuvant treatment with 5-FU. Capecitabine demonstrated an
improved safety profile compared with 5-FU/LV and is associated
with a very low incidence of alopecia and myelosuppression
(Cassidy et al, 2002). The only adverse event occurring more
frequently with capecitabine than with 5-FU/LV is hand–foot
syndrome, which is easily managed by treatment interruption and
dose reduction, and is never life threatening. Phase II studies of
capecitabine in gastric and pancreatic cancer have also shown
promising activity and a favourable safety profile (Cartwright et al,
2002; Hong et al, 2002; Koizumi et al, 2003).
In addition, capecitabine is a highly active component of
combination treatment for metastatic CRC. A large international
study has shown that capecitabine is highly active in combination
with oxaliplatin, achieving a response rate of 55%, median TTP of
7.7 months and overall survival of 19.5 months as first-line therapy
(Cassidy et al, 2004). The combination of capecitabine and
irinotecan is supported by their different mechanisms of action.
In preclinical evaluation, the combination of capecitabine and
irinotecan demonstrated at least additive activity and was highly
curative in tumour xenograft models (Cao et al 2001; Hapke et al,
2001). Additionally, capecitabine and irinotecan show only partial
overlap of key toxicities. The predominant adverse events
associated with irinotecan are neutropenia and diarrhoea. In a
phase II study of 3-weekly irinotecan in patients with metastatic
CRC, Grade 3/4 neutropenia and diarrhoea were observed
in 40 and 26% of patients, respectively (Van Cutsem et al, 1999).
Capecitabine is also associated with diarrhoea, but only
minimal myelosuppression. In an integrated analysis of two large
phase III trials of capecitabine in patients with metastatic
CRC, Grade 3/4 diarrhoea was reported in 13% of patients, but
Grade 3/4 neutropenia was observed in only 2% of patients
(Cassidy et al, 2002). The significantly lower rates of diarrhoea and
neutropenia occurring with capecitabine compared with 5-FU/LV
(Mayo Clinic regimen) observed in these trials suggest that
capecitabine may also be a better-tolerated combination partner
for irinotecan.
The metabolic activation of both irinotecan and capecitabine is
dependent on hepatic carboxylesterase activity. Irinotecan is
cleaved by hepatic carboxylesterases to form the active metabolite
SN-38, which is a potent inhibitor of topoisomerase 1 (Kuhn,
1998). As discussed above, the first step of the tumour-specific
activation of capecitabine is conversion to the intermediate
50-DFCR by hepatic carboxylesterase (Miwa et al, 1998). Conse-
quently, there is potential for pharmacokinetic interaction between
irinotecan and capecitabine.
There is therefore a clear rationale for investigating capecitabine
in combination with irinotecan in patients with advanced
gastrointestinal cancer. The current phase I clinical and pharma-
cokinetic study assessed the feasibility of combination therapy
with capecitabine and irinotecan (XELIRI) in patients with
advanced/metastatic gastrointestinal tumours. The primary objec-
tive of the study was to determine the maximum-tolerated dose
(MTD) and dose-limiting toxicities (DLTs) of capecitabine,
administered twice daily, on days 2–15 in combination with
irinotecan, administered as a 90-min infusion, on day 1 of a 21-day
treatment cycle. In addition, the study investigated whether
significant pharmacokinetic interactions occur between the
component agents, and evaluated the safety profile and antitumour
activity of the XELIRI regimen.
PATIENTS AND METHODS
This phase I, open-label, dose-escalation study of capecitabine and
irinotecan combination therapy in patients with solid tumours of
the gastrointestinal tract was conducted in three French Cancer
Centres, in accordance with the International Good Practice
principles and local ethical and regulatory requirements.
Eligibility
The study included patients aged 18–75 years with histologically
proven gastrointestinal tract cancer and no satisfactory options for
further treatment. Patients were required to have a life expectancy
X3 months, Eastern Cooperative Oncology Group (ECOG)
performance status 0–2, absolute neutrophil count X2000ml
 1,
platelet count X100000ml
 1, haemoglobin X10gdl
 1, serum
creatinine p125mmoll
 1, total bilirubin p1.25 times the upper
normal limit (UNL), transaminases p3 times UNL, as well as
prothrombin time and international normalised ratio within
normal limits, and no evidence of severe infection, intestinal
occlusion or subocclusion, or central nervous system metastasis.
All patients provided written informed consent prior to study-
specific screening procedures.
Patients were excluded from the study if they had received
previous treatment with a topoisomerase inhibitor (irinotecan or
other) or capecitabine, or had previously experienced allergic
reactions to 5-FU. Additionally, patients were excluded if they had
previously received total body irradiation or abdominopelvic
radiation. Patients undergoing major abdominal surgery within 4
weeks of study entry or those with a history of serious
cardiovascular disorder or renal, hepatic or metabolic disease that
could potentially compromise the metabolism of the study drug
were also excluded. Additional exclusion criteria included treat-
ment with 5-FU within 4 weeks of study entry or with mitomycin
C, nitrosourea compounds or extended radiation therapy within 6
weeks of study entry.
Drug administration and dose escalation
Escalating doses of irinotecan (200–350mgm
 2) were adminis-
tered in an intravenous infusion over 90min on day 1 of a 3-weekly
treatment cycle. Oral capecitabine (700–1250mgm
 2) was admi-
nistered twice daily (approximately 12h apart), within 30min after
a meal, on days 2–15. Antiemetic and antidiarrhoeal treatments
and preventative therapy for irinotecan-induced early-onset
anticholinergic syndrome were administered according to the
policies at each centre.
At least three patients were recruited at each dose level and the
dose was escalated when three patients had completed two
treatment cycles without DLTs. If one or more of the three
patients developed a DLT, the dose level was expanded to a total of
at least six patients. If fewer than three of the six patients
experienced a DLT, dose escalation was permitted, but if three or
more of six patients experienced a DLT at a single dose level, that
dose level was identified as the MTD. The dose level preceding the
MTD was identified as the recommended dose and three additional
patients were treated at this dose. No intrapatient dose escalation
was permitted.
The maximum duration of treatment was six cycles. After this
time, further treatment could be administered at the discretion of
the investigator.
Dose-limiting toxicities
Adverse events were classified according to the National Cancer
Institute (NCI) Common Toxicity Criteria (CTC) Version 2.0.
(1999). Any of the following toxicities occurring during the first
two cycles of chemotherapy were considered dose limiting: any
Grade 3 or 4 nonhaematologic toxicity (excluding alopecia and
nausea); Grade 4 neutropenia or Grade 4 thrombocytopenia lasting
for more than 7 days or accompanied by concomitant infection or
bleeding, respectively; febrile neutropenia; nausea or vomiting
preventing intake of capecitabine for at least 3 consecutive days;
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sand any treatment-related adverse event causing a delay in the
administration of the second treatment cycle.
Patient and tumour evaluation
Patients were evaluated at baseline, on a weekly basis during the
first two treatment cycles and at 3-weekly intervals thereafter.
Evaluations included a complete clinical examination and record-
ing of all adverse events, including severity and outcome.
Complete blood counts (CBC) were performed at least twice
weekly and blood chemistry analysis was performed weekly. A
clinical tumour evaluation was performed during these visits, with
the objective of detecting disease progression. A final evaluation,
including a complete clinical examination, assessment of adverse
events, CBC and blood chemistry analysis was conducted at the
end of treatment.
In patients with measurable disease, tumour evaluation, based
on World Health Organization (WHO) criteria, was performed at
baseline, every 3 weeks for 6 weeks and at 9-weekly intervals
thereafter. The best overall response was defined as the best
response recorded from the start of treatment to disease
progression. Complete responses (CR) and partial responses
(PR) were confirmed by a second tumour assessment after 4
weeks. TTP was defined as the time from the start of treatment
until disease progression.
Pharmacokinetic evaluation
Pharmacokinetic evaluation was conducted during cycles 1 and 2.
To determine the pharmacokinetics of irinotecan, blood was
sampled for analysis of irinotecan and its metabolites 7-ethyl-10-
hydroxycamptothecin (SN-38), SN-38 glucuronide and 7-ethyl-10-
[4-N-(5-aminopeptanoic acid)-1-piperidino]-carbonyloxycamp-
tothecin (APC) on day 1. Sampling times for irinotecan analysis
included pretreatment and 3.0, 3.5, 9.5, 11.5, and 24.0h after the
start of the 90-min intravenous infusion. Plasma was recovered
immediately after blood collection and the concentrations of
irinotecan and its metabolites were measured by high-performance
liquid chromatography (HPLC) as described previously (Rivory
and Robert, 1995). Estimates of pharmacokinetic parameters of
irinotecan and SN-38 were obtained by Bayesian analysis and
POSTHOC option using the NONMEM program (version V, level
1.1, GloboMax Inc., Hanover, MD, USA) and a database of 67
previously evaluated samples (Chabot et al, 1995). The plasma
area under the concentration–time curves (AUCs) of SN-38
glucoronide were determined using a limited-sampling method
with stepwise linear regression, as recommended by Mick et al
(1996). Plasma AUC of APC was determined by trapezoidal
rule up to 24h after the beginning of the irinotecan infusion
(without extrapolation to infinity). The AUC values of irinotecan
and its metabolites were compared between cycle 1 (before
capecitabine administration) and cycle 2 (after a 2-week period
of capecitabine treatment and 1-week wash-out) by using a paired
Student’s t-test.
For analysis of capecitabine and its metabolites, blood samples
were collected on day 2 before capecitabine administration and at
0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0 and 12.0h after administration. Plasma
was recovered immediately after blood collection and concentra-
tions of capecitabine and its metabolites 50-DFCR, 50-DFUR and 5-
FU were measured using a validated reversed-phase HPLC
technique with ultraviolet detection, slightly modified from the
one described previously (Reigner et al, 1998). The AUC values
were calculated using the linear trapezoidal rule. For capecitabine
and its metabolites, the pharmacokinetic analysis was performed
using the MicroPharm software (S Urien, Inserm-CRH, Saint-
Cloud, France) and the Statview program (Abacus Concept Inc.,
USA) was used for the statistical analysis of the pharmacokinetic
parameters.
RESULTS
Patient characteristics and disposition
A total of 27 patients were recruited to the study, from November
1999 to December 2001, of whom all were evaluable for safety, with
23 evaluable for tumour response. Patient characteristics are
summarised in Table 1. The median age was 58 years (range 33–72
years) and the majority of patients (93%) had ECOG performance
status 0 or 1. Most patients (78%) had CRC, four patients (15%)
had gastric cancer and two patients (7%) had pancreatic cancer.
With the exception of one tumour with epidermal histology, all
tumours were adenocarcinomas and all patients had stage IV
disease at study entry. Most patients had undergone prior
surgery (85%) and had received previous chemotherapy, including
5-FU (81%).
DLTs and recommended dose level
No DLTs occurred in patients treated at dose levels 1–3 (Table 2).
At dose level 4 (capecitabine 1000mgm
 2 twice daily and
irinotecan 250mgm
 2), one patient developed Grade 3 diarrhoea
and Grade 4 neutropenia with septicaemia on day 6 of the first
cycle. No further DLTs were experienced by the six patients
treated at this dose level. Three of six patients treated at dose level
5 (capecitabine 1150mgm
 2 twice daily and irinotecan
250mgm
 2) developed DLTs: one patient experienced Grade 3
diarrhoea and abdominal pain by day 11 of the first cycle;
one patient experienced Grade 3 diarrhoea and Grade 4
neutropenia on day 8 of the second cycle; and a further patient
developed Grade 4 diarrhoea and Grade 3 vomiting by day 15 of
the second cycle. To confirm the recommended dose, three
additional patients were treated at dose level 4. As one patient
Table 1 Baseline patient demographics (n¼27)
Parameter No. (%)
Median age, years (range) 58 (33–72)
Gender
Male 18 (67)
Female 9 (33)
ECOG performance status
0 13 (48)
1 12 (45)
2 2 (7)
Primary tumour site
Colorectal 21 (78)
Gastric 4 (15)
Pancreas 2 (7)
Histology
Adenocarcinoma 26 (96)
Squamous cell carcinoma 1 (4)
Median number of metastatic lesions (range) 3 (1–5)
Prior treatment
Surgery 23 (85)
Radiotherapy 6 (22)
No. of prior chemotherapy regimens
a
0 5 (19)
1 13 (48)
2 3 (11)
42 6 (22)
ECOG¼Eastern Cooperative Oncology Group; 5-FU¼5-fluorouracil.
aAll regimens,
including 5-FU.
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swas not evaluable for safety, a total of 10 patients were treated at
this dose level. No further DLTs were observed. Therefore, the
MTD was dose level 5 (capecitabine 1150mgm
 2 twice daily and
irinotecan 250mgm
 2) and dose level 4 (capecitabine
1000mgm
 2 twice daily and irinotecan 250mgm
 2) was identified
as the recommended dose for further phase II study. Overall,
among the 10 patients treated at dose level 4, only one patient
experienced a DLT.
Safety profile
A total of 103 treatment cycles were administered to 27 patients
and 16 patients received at least four cycles. The median duration
of treatment was 2.8 months (range 0.07–16.1 months). Of the 10
patients treated at dose level 4, six patients received four or more
treatment cycles. No cumulative toxicities were observed in
patients completing more than four cycles.
The most frequent treatment-related adverse events were
gastrointestinal disturbances, and the majority of cases were
mild or moderate in intensity. Table 3 shows the incidence of
Grade 3/4 adverse events by dose level. The only Grade 4
adverse events were diarrhoea in two patients (treated at dose
level 5), nausea and vomiting, each in one patient (treated at
dose level 4), and neutropenia in two patients (one treated
at dose level 4, the other at dose level 5). Notably, only one
patient (treated at dose level 3) experienced Grade 3 hand–foot
syndrome.
Pharmacokinetics
During cycle 1, plasma samples for pharmacokinetic studies
were obtained from 23 patients on days 1 and 2. Pharmacokinetic
data were evaluated in 23 patients during cycle 2. The mean AUC
values for irinotecan and its metabolites are shown in Table 4.
There were no significant differences between cycles 1 and 2 in
AUC values for both irinotecan and SN-38. The AUC values
of SN-38 glucuronide and APC were significantly different
(Po0.05) between cycles 2 and 1 (% change from cycles 1 to 2:
þ15.3 and  19.3%, respectively). The mean AUC values for
capecitabine, 50-DFCR, 50-DFUR and 5-FU are shown in Table 5.
No significant differences were observed between cycles 1 and 2 at
dose levels 1–5.
Antitumour activity
Among 23 evaluable patients, an objective response to treatment
was observed in two pretreated patients with CRC: a CR in one
patient treated at dose level 4 and a PR in one patient treated at
dose level 5 (Table 6). In addition, four patients achieved disease
stabilisation. Among the eight evaluable patients treated at dose
level 4 (the recommended dose for phase II evaluation), median
TTP was 3.5 months (range 1.4–10.2 months).
DISCUSSION
This study demonstrates that XELIRI (capecitabine plus irinote-
can) is a feasible and promising new treatment for patients with
metastatic gastrointestinal tumours. The recommended dosing
schedule was identified as capecitabine 1000mgm
 2 twice daily on
days 2–15 in combination with irinotecan 250mgm
 2, adminis-
tered as a 90-min infusion, on day 1 of every 21-day cycle.
The benefits of combination therapy with irinotecan and 5-FU
are well established, with phase III studies showing that the
addition of irinotecan to intravenous 5-FU/LV significantly
improves efficacy, including overall survival, compared with 5-
FU/LV alone in patients with previously untreated metastatic CRC
(Douillard et al, 2000; Saltz et al, 2000). It has been suggested that
continuous infusion 5-FU may be a safer option in combination
with irinotecan than bolus 5-FU (Rothenberg et al, 2001).
Capecitabine is an oral agent providing chronic dosing that
mimics continuous infusion 5-FU with a favourable safety profile
compared with bolus intravenous 5-FU/LV (Hoff et al, 2001; Van
Cutsem et al, 2001; Cassidy et al, 2002). Twice daily dosing with
oral capecitabine offers numerous opportunities for dose adjust-
ment during the treatment cycle, allowing safety to be readily
optimised in patients receiving XELIRI. In addition, tumour-
activated capecitabine may offer an enhanced therapeutic index via
the generation of 5-FU preferentially in tumour. Replacement of
infused 5-FU/LV with oral capecitabine is expected to simplify and
improve the convenience of irinotecan/fluoropyrimidine combina-
tion therapy, because the XELIRI regimen requires only one clinic
visit per 3-week cycle and avoids the inconvenience and potential
complications associated with the protracted intravenous access
required with infusional regimens.
The current phase I/pharmacokinetic study has demonstrated
the feasibility of XELIRI. The MTD was identified as irinotecan
Table 2 Incidence of DLTs during dose escalation
No. of patients
Dose level Capecitabine (mgm
 2 twice daily) Irinotecan (mgm
 2) Treated With DLT DLTs
1 700 200 4 0
2 850 200 3 0
3 1000 200 4 0
4 1000 250 10 1 Grade 3 diarrhoea, Grade 4 neutropenia/septicaemia
5 1150 250 6 3 Grade 3 diarrhoea/abdominal pain
Grade 3 diarrhoea/Grade 4 neutropenia
Grade 4 diarrhoea/Grade 3 vomiting
DLTs¼dose-limiting toxicities.
Table 3 Grade 3/4 treatment-related adverse events
Adverse events: Grade 3/Grade 4
Dose level 1 (n¼4) 2 (n¼3) 3 (n¼4) 4 (n¼10) 5 (n¼6)
Capecitabine (mgm
 2
twice daily)
700 850 1000 1000 1150
Irinotecan (mgm
 2) 200 200 200 250 250
Nausea 1/0 0/0 1/0 0/1 2/0
Diarrhoea 1/0 0/0 1/0 2/0 1/2
Vomiting 1/0 0/0 0/0 0/1 2/0
Stomatitis 0/0 0/0 0/0 0/0 1/0
Asthenia 1/0 0/0 1/0 0/0 0/0
Abdominal pain 0/0 0/0 0/0 0/0 1/0
Hand–foot syndrome 0/0 0/0 1/0 0/0 0/0
Leucopenia 1/0 0/0 0/0 1/0 1/0
Lymphopenia 0/0 0/0 0/0 0/0 2/0
Neutropenia 2/0 0/0 0/0 1/1 0/1
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s250mgm
 2 as a 90-min infusion on day 1 plus oral capecitabine
1150mgm
 2 twice daily on days 2–15, every 21 days. DLTS were
assessed during the first two cycles of treatment in order to
evaluate the potential for cumulative toxicity. The principal DLTs
were diarrhoea and neutropenia, which are typical of fluoropyr-
imidine/irinotecan combinations (Saltz et al, 1996; Vanhoefer et al,
1999). The recommended dose is capecitabine 1000mgm
 2 twice
daily on days 2–15 combined with irinotecan 250mgm
 2
administered as a 90-min infusion, on day 1 of every 21-day cycle.
Among the 10 patients treated at this dose level, only one patient
experienced a DLT.
Overall, the combination demonstrated a predictable safety
profile, which was consistent with the known toxicity profiles of
the single agents. The most commonly occurring adverse events
were gastrointestinal disturbances, asthenia and neutropenia.
However, Grade 1/2 diarrhoea occurred in the majority (75%) of
patients experiencing this side effect, indicating that it was
effectively managed in most patients by supportive measures and
antidiarrhoeal medication. Similarly, Grade 1/2 neutropenia
occurred in 75% of patients experiencing this side effect. Grade
3 and 4 neutropenia occurred in only four and two patients,
respectively. Notably, Grade 3 hand–foot syndrome, a cutaneous
side effect that is typical of infused fluoropyrimidines, was
observed in only one patient.
Hepatic carboxylesterase is involved in the metabolism of
capecitabine and irinotecan (Kuhn, 1998; Miwa et al, 1998). A
pharmacokinetic evaluation was therefore performed to confirm
the feasibility of administering capecitabine and irinotecan in
combination and to determine the potential for interactions
between these two agents. The similar AUC values for irinotecan
and its metabolites during cycles 1 and 2 indicate that the
administration of capecitabine does not impact significantly on
either the AUC of irinotecan or SN-38 in this administration
schedule. However, it should be noted that the drug-free period
between treatment cycles precludes any definitive conclusions
about the potential direct pharmacokinetic impact of capecitabine
on irinotecan metabolism. Moreover, statistical differences were
observed for the AUCs of nonactive metabolites (i.e. SN-38
glucuronide and APC), but the absolute change was less than
20%. Taken together, the changes in AUCs observed between
cycles 1 and 2 (i.e. þ16.4% for SN-38, þ15.3% for SN-38
glucuronide and  19.3% for APC) indicate that the metabolism of
irinotecan was modified between cycles without any change in the
overall clearance of irinotecan. So far, no systemic changes in the
Table 4 Mean AUC values for irinotecan and its metabolites
AUC lgml
 1h (CV, %)
Irinotecan SN-38 SN-38 glucuronide APC
Cycle 1 Cycle 2 Cycle 1 Cycle 2 Cycle 1 Cycle 2 Cycle 1 Cycle 2
Dose levels 1–3 (n¼10) 11.6 (25) 11.9 (28) 0.518 (62) 0.539 (57) 0.838 (33) 0.909 (43)
a 2.24 (59)
a 2.25 (44)
Dose levels 4 and 5 (n¼13) 14.9 (41) 16.0 (51) 0.587 (113) 0.640 (87) 0.876 (66) 1.043 (77) 1.61 (37)
b 1.34 (40)
a
Cycle 2 vs cycle 1 (% change795% CI) +6.2 (710.1) +16.4 (720.2) +15.3 (713.0)  19.3% (715.3)
P-value NS NS o0.05 o0.05
AUC¼area under the curve; SN-38¼7-ethyl-10-hydroxycamptothecin; APC¼7-ethyl-10-[4-N-(5-aminopeptanoic acid)-1-piperidino]-carbonyloxycamptothecin; NS¼not
significant.
aNot available for one patient.
bNot available for two patients.
Table 5 Mean AUC values for capecitabine, 5-FU and its metabolites
AUC(0–12h) (s.d.) (mgml
 1h)
Capecitabine 5-FU 50-DFCR 50-DFUR
Capecitabine twice daily dose (mgm
 2) Cycle 1 Cycle 2 Cycle 1 Cycle 2 Cycle 1 Cycle 2 Cycle 1 Cycle 2
700 3652 (1234) 3208 (820) 555 (157) 322 (130) 1929 N/A 2087 (910) 13495 (4335) 11179 (1300)
850 4343 (793) 4248 (1156) 407 (70) 465 (210) 1286 (586) 1890 (1164) 11916 (1518) 10887 (1914)
1000 7700 (3046) 7322 (3620) 478 (172) 598 (326) 6149 (3818) 7285 (3610) 14341 (6769) 15836 (3048)
1150 11553 (5814) 11188 (7377) 621 (156) 516 (189) 9967 (3526) 11110 (2520) 18001 (2572) 16289 (5383)
AUC¼area under the curve; s.d.¼standard deviation; 5-FU¼5-fluorouracil; DFCR¼50-deoxy-5-fluorocytidine; DFUR¼50-deoxy-5-fluorouridine; N/A¼not available.
Table 6 Antitumour activity of XELIRI – best response
Dose level Irinotecan (mgm
 2) Capecitabine (mgm
 2 twice daily) CR PR Stable disease Progressive disease
1( n¼3) 200 700 3
2( n¼3) 200 850 3
3( n¼4) 200 1000 1 3
4( n¼8) 250 1000 1
a 25
5( n¼5) 250 1150 1
b 13
Total (n¼23) 11 4 1 7
CR¼complete response; PR¼partial response.
aPatient with colorectal cancer (CRC) who had previously demonstrated a partial response to 5-FU/oxaliplatin.
bPatient with
CRC who had previously demonstrated PR and CR, as well as disease stabilisation, after treatment with three previous 5-FU-based regimens.
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described from cycles 1 to 2 when the agents are administered
alone. Intraindividual variability of 14, 35 and 38% between cycles
have been observed for plasma AUC of irinotecan, SN-38 and SN-
38 glucuronide, respectively, but the number of cycles delivered
did not significantly influence any of the pharmacokinetic
parameters (Canal et al, 1996). Therefore, the changes in AUC
observed in the current study are most likely attributable to the
interaction of irinotecan with capecitabine. The trend we observed
is consistent with the observation by Falcone et al (2001) that the
AUC of SN-38 is increased when irinotecan infusion is preceded by
5-FU. In this study, the SN-38 AUC was 40% lower when irinotecan
preceded 5-FU administration compared with the reverse
sequence. However, whereas in the Falcone study 5-FU was
administered immediately before irinotecan, in the current study,
there was a 1-week wash-out period between administration of
capecitabine and irinotecan. This schedule difference may explain
the greater influence of 5-FU on irinotecan metabolism in the
study by Falcone et al (2001), compared with the modest changes
in the current study.
As expected, the AUC of capecitabine appears to increase
linearly with dose escalation during both cycles 1 and 2. However,
no significant differences in the AUC of capecitabine were
observed between cycles 1 and 2; therefore, confirming that
irinotecan does not have a major impact on the metabolism of
capecitabine. This observation is consistent with the fact that no
cumulative toxicity was observed at dose levels 4 and 5 in patients
receiving more than two cycles.
Preliminary data from other pilot studies evaluating XELIRI
(irinotecan 240–300mgm
 2 on day 1, or 100mgm
 2 on days 1
and 8, with intermittent oral capecitabine 1000mgm
 2 adminis-
tered twice daily on days 1–14, every 3 weeks) in the first-line
treatment of metastatic CRC have demonstrated promising activity
with an acceptable safety profile (Bajetta et al, 2001; Kerr et al,
2002; Borner et al, 2003; Grothey et al, 2003). The current schedule
affords convenience benefits compared with XELIRI regimens
requiring weekly administration of irinotecan.
In a recent phase I study evaluating weekly intravenous
irinotecan and capecitabine administered twice daily on days 1–
14 of a 21-day cycle, the dose recommended for further evaluation
was irinotecan 70mgm
 2 and capecitabine 1000mgm
 2 (Tewes
et al, 2003). The study, which evaluated first-line XELIRI in
patients with metastatic CRC, demonstrated good activity, with an
overall response rate of 38%. It is worth noting that a UK/Dutch
phase I study has identified a recommended regimen identical to
that of the current study (Kerr et al, 2002). Preliminary data
reported from a phase II trial show that this regimen (irinotecan
250mgm
 2 on day 1, followed by intermittent oral capecitabine
1000mgm
 2 twice daily for 14 days, every 3 weeks) is highly
active as first-line therapy for metastatic CRC, achieving an
objective response rate of 42% and median TTP of 7.1 months
(Patt et al, 2003).
The response rate and median TTP achieved with XELIRI
compare favourably with the results from randomised trials
evaluating either infused or bolus 5-FU in combination with
irinotecan as first-line therapy (Douillard et al, 2000; Saltz et al,
2000; Goldberg et al, 2003). In the current study, the vast majority
of patients had received prior chemotherapy for treatment of
advanced disease and more than one-third of patients had received
multiple chemotherapy regimens. All chemotherapy-pretreated
patients had received at least one 5-FU-based regimen. One patient
treated at the recommended dose achieved a CR and a further
patient treated at the MTD demonstrated a PR. Notably, both
patients demonstrating a response to XELIRI had received prior
treatment with 5-FU. Furthermore, in the patient demonstrating a
PR, the current regimen was administered in the fourth-line
setting. A further two patients experienced disease stabilisation at
the recommended dose.
In conclusion, the XELIRI regimen is shown to be a feasible and
clinically active chemotherapy regimen in patients with advanced
gastrointestinal cancer. XELIRI offers a simplified regimen that is
less cumbersome for patients and avoids the discomfort and
complications associated with the central venous access required
with continuous infusion 5-FU. The lack of pharmacokinetic
interaction between capecitabine and irinotecan lends further
support for evaluation of this XELIRI regimen in the phase II
setting. Accordingly, the European Organization for the Research
and Treatment of Cancer is currently evaluating XELIRI vs
irinotecan plus infusional 5-FU/LV as first-line treatment for
advanced CRC.
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